{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:15:37Z","timestamp":1773285337147,"version":"3.50.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":509,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100008171","name":"Minneapolis Heart Institute Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008171","name":"Minneapolis Heart Institute Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with refractory angina who are suboptimal candidates for further revascularization have improved exercise time, decreased angina frequency, and reduced major adverse cardiac events with intramyocardial delivery of CD34+ cells. However, the effect of CD34+ cell therapy on health care expenditures before and after treatment is unknown. We determined the effect of CD34+ cell therapy on cardiac-related hospital visits and costs during the 12\u2009months following stem cell injection compared with the 12\u2009months prior to injection. Cardiac-related hospital admissions and procedures were retrospectively tabulated for patients enrolled at one site in one of three double-blinded, placebo-controlled CD34+ trials in the 12\u2009months before and after intramyocardial injections of CD34+ cells vs placebo. Fifty-six patients were randomized to CD34+ cell therapy (n = 37) vs placebo (n = 19). Patients randomized to cell therapy experienced 1.57\u2009\u00b1\u20091.39 cardiac-related hospital visits 12\u2009months before injection, compared with 0.78\u2009\u00b1\u20091.90 hospital visits 12\u2009months after injection, which was associated with a 62% cost reduction translating to an average savings of $5500 per cell therapy patient. Patients in the placebo group also demonstrated a reduction in cardiac-related hospital events and costs, although to a lesser degree than the CD34+ group. Through 1 January 2019, 24% of CD34+ subjects died at an average of 6.5\u2009\u00b1\u20092.4\u2009years after enrollment, whereas 47% of placebo patients died at an average of 3.7\u2009\u00b1\u20091.9\u2009years after enrollment. In conclusion, CD34+ cell therapy for subjects with refractory angina is associated with improved mortality and a reduction in hospital visits and expenditures for cardiac procedures in the year following treatment.<\/jats:p>\n               <jats:sec>\n                  <jats:title\/>\n               <\/jats:sec>","DOI":"10.1002\/sctm.20-0046","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T21:35:52Z","timestamp":1591997752000},"page":"1147-1152","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["CD34+ cell therapy significantly reduces adverse cardiac events, health care expenditures, and mortality in patients with refractory angina"],"prefix":"10.1093","volume":"9","author":[{"given":"Grace L.","family":"Johnson","sequence":"first","affiliation":[{"name":"1 Minneapolis Heart Institute Foundation Abbott Northwestern Hospital, Minneapolis, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy D.","family":"Henry","sequence":"additional","affiliation":[{"name":"1 Minneapolis Heart Institute Foundation Abbott Northwestern Hospital, Minneapolis, Minnesota, USA"},{"name":"2 Cardiovascular Division The Christ Hospital, Cincinnati, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Povsic","sequence":"additional","affiliation":[{"name":"3 Division of Cardiology Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas W.","family":"Losordo","sequence":"additional","affiliation":[{"name":"4 Caladrius Biosciences, Rye Brook, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross F.","family":"Garberich","sequence":"additional","affiliation":[{"name":"1 Minneapolis Heart Institute Foundation Abbott Northwestern Hospital, Minneapolis, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larissa I.","family":"Stanberry","sequence":"additional","affiliation":[{"name":"1 Minneapolis Heart Institute Foundation Abbott Northwestern Hospital, Minneapolis, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig E.","family":"Strauss","sequence":"additional","affiliation":[{"name":"1 Minneapolis Heart Institute Foundation Abbott Northwestern Hospital, Minneapolis, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay H.","family":"Traverse","sequence":"additional","affiliation":[{"name":"1 Minneapolis Heart Institute Foundation Abbott Northwestern Hospital, Minneapolis, Minnesota, USA"},{"name":"5 Cardiovascular Division University of Minnesota School of Medicine, Minneapolis, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"2022022809424244100_sct312749-bib-0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcin.2019.08.055","article-title":"Refractory angina: from pathophysiology to new therapeutic nonpharmacological technologies","volume":"13","author":"Gallone","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"2022022809424244100_sct312749-bib-0002","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/euhj.2001.2706","article-title":"The problem of chronic refractory angina. Report from the ESC joint study group on the treatment of refractory angina","volume":"23","author":"Mannheimer","year":"2002","journal-title":"Eur Heart J"},{"key":"2022022809424244100_sct312749-bib-0003","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrcardio.2013.200","article-title":"Treatment of refractory angina in patients not suitable for revascularization","volume":"11","author":"Henry","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"2022022809424244100_sct312749-bib-0004","author":"Kones"},{"key":"2022022809424244100_sct312749-bib-0005","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0002-9149(99)00387-2","article-title":"Direct myocardial revascularization and angiogenesis\u2014how many patients might be eligible?","volume":"84","author":"Mukherjee","year":"1999","journal-title":"Am J Cardiol"},{"key":"2022022809424244100_sct312749-bib-0006","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ijcard.2009.09.538","article-title":"Fatality, morbidity and quality of life in patients with refractory angina pectoris","volume":"147","author":"Andr\u00e9ll","year":"2017","journal-title":"Int J Cardiol"},{"key":"2022022809424244100_sct312749-bib-0007","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001287","article-title":"Predictors of long-term clinical endpoints in patients with refractory angina","volume":"4","author":"Povsic","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2022022809424244100_sct312749-bib-0008","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1161\/01.CIR.0000128596.49339.05","article-title":"Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies","volume":"109","author":"Losordo","year":"2004","journal-title":"Circulation"},{"key":"2022022809424244100_sct312749-bib-0009","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/86498","article-title":"Neovascularization of ischemic myocardium by human bone-marrow\u2013derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function","volume":"7","author":"Kocher","year":"2001","journal-title":"Nat Med"},{"key":"2022022809424244100_sct312749-bib-0010","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1161\/01.CIR.0000046450.89986.50","article-title":"Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia","volume":"107","author":"Kawamoto","year":"2003","journal-title":"Circulation"},{"key":"2022022809424244100_sct312749-bib-0011","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1161\/CIRCULATIONAHA.106.644518","article-title":"CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells","volume":"114","author":"Kawamoto","year":"2006","journal-title":"Circulation"},{"key":"2022022809424244100_sct312749-bib-0012","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1161\/CIRCULATIONAHA.106.687376","article-title":"Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I\/IIa double-blind, randomized controlled trial","volume":"115","author":"Losordo","year":"2007","journal-title":"Circulation"},{"key":"2022022809424244100_sct312749-bib-0013","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1161\/CIRCRESAHA.111.245993","article-title":"Intramyocardial, autologous CD34+ cell therapy for refractory angina","volume":"109","author":"Losordo","year":"2011","journal-title":"Circ Res"},{"key":"2022022809424244100_sct312749-bib-0014","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jcin.2016.05.003","article-title":"The RENEW trial","volume":"9","author":"Povsic","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"2022022809424244100_sct312749-bib-0015","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/eurheartj\/ehx764","article-title":"Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials","volume":"39","author":"Henry","year":"2018","journal-title":"Eur Heart J"},{"key":"2022022809424244100_sct312749-bib-0016","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3727\/096368914X681595","article-title":"Long-term and sustained therapeutic results of a specific promonocyte cell formulation in refractory angina: ReACT\u00ae (Refractory Angina Cell Therapy) clinical update and cost-effective analysis","volume":"24","author":"Hossne","year":"2015","journal-title":"Cell Transplant"},{"key":"2022022809424244100_sct312749-bib-0017","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ahj.2013.03.003","article-title":"A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study","volume":"165","author":"Povsic","year":"2013","journal-title":"Am Heart J"},{"key":"2022022809424244100_sct312749-bib-0018","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijcard.2015.09.103","article-title":"Reduction of healthcare utilization after bone marrow cell therapy for refractory angina pectoris","volume":"202","author":"Rodrigo","year":"2016","journal-title":"Int J Cardiol"},{"key":"2022022809424244100_sct312749-bib-0019","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/ccd.27707","article-title":"Revascularization in \"no option\" patients with refractory angina: frequency, etiology and outcomes","volume":"92","author":"Sharma","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"key":"2022022809424244100_sct312749-bib-0020","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1093\/eurheartj\/eht165","article-title":"Long-term survival in patients with refractory angina","volume":"34","author":"Henry","year":"2013","journal-title":"Eur Heart J"},{"key":"2022022809424244100_sct312749-bib-0021","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics\u20142019 update: a report from the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fsctm.20-0046","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/sctm.20-0046","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/sctm.20-0046","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/9\/10\/1147\/42627391\/stcltm_9_10_1147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/9\/10\/1147\/42627391\/stcltm_9_10_1147.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T09:58:42Z","timestamp":1646042322000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/9\/10\/1147\/6406944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":21,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,6,12]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/sctm.20-0046","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10,1]]},"published":{"date-parts":[[2020,6,12]]},"assertion":[{"value":"2020-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}